HMGA and Cancer

被引:130
作者
Fedele, Monica
Fusco, Alfredo [1 ]
机构
[1] Univ Naples Federico II, Ist Endocrinol & Oncol Sperimentale, Dipartimento Biol & Patol Cellulare & Mol, Fac Med & Chirurgia Napoli,CNR, I-80131 Naples, Italy
来源
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS | 2010年 / 1799卷 / 1-2期
关键词
High Mobility Group protein; Chromatinic protein; Mesenchymal tumor; Pituitary adenomas; Carcinogenesis; MOBILITY GROUP A1; NF-KAPPA-B; PULMONARY CHONDROID HAMARTOMAS; HMGI(Y) PROTEIN EXPRESSION; I-C PROTEIN; GENE-EXPRESSION; TRANSGENIC MICE; GROUP A2; MALIGNANT PHENOTYPE; TRANSCRIPTIONAL ACTIVATION;
D O I
10.1016/j.bbagrm.2009.11.007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Long-standing studies have clearly established that the architectural chromatinic proteins High Mobility Group A (HMGA) are among the most widely expressed cancer-associated proteins. Indeed, their overexpression represents a constant feature of human malignancies, and correlates with a poor prognosis. Moreover, HMGA dysregulation, as a result of specific chromosomal rearrangements, occurs in a broad variety of common benign mesenchymal tumors, making HMGA genes among the most commonly rearranged genes in human neoplasms. Nevertheless, recent data propose a critical role of HMGA overexpression also in the generation of pituitary adenomas. Here, we review the involvement of HMGA proteins in cancer, analyzing the mechanisms underlying their crucial role in tumorigenesis, and, finally, discuss the potentiality of a cancer treatment based on HMGA targeting. (C) 2009 Elsevier B.V. All rights reserved.
引用
收藏
页码:48 / 54
页数:7
相关论文
共 125 条
  • [61] 2-T
  • [62] Ten pulmonary chondroid hamartomas with chromosome 6p21 breakpoints within the HMG-I(Y) gene or its immediate surroundings
    Kazmierczak, B
    Wanschura, S
    Rommel, B
    Bartnitzke, S
    Bullerdiek, J
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (17) : 1234 - 1236
  • [63] Gemcitabine resistance in pancreatic cancer: Picking the key players
    Kim, Michael P.
    Gallick, Gary E.
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1284 - 1285
  • [64] The tumor suppressor microRNA let-7 represses the HMGA2 oncogene
    Lee, Yong Sun
    Dutta, Anindya
    [J]. GENES & DEVELOPMENT, 2007, 21 (09) : 1025 - 1030
  • [65] Overexpression of HMGA1 promotes anoikis resistance and constitutive Akt activation in pancreatic adenocarcinoma cells
    S-S Liau
    A Jazag
    K Ito
    E E Whang
    [J]. British Journal of Cancer, 2007, 96 (6) : 993 - 1000
  • [66] High mobility group AT-Hook 1 (HMGA1) is an independent prognostic factor and novel therapeutic target in pancreatic adenocarcinoma
    Liau, Siong-Seng
    Rocha, Flavio
    Matros, Evan
    Redston, Mark
    Whang, Edward
    [J]. CANCER, 2008, 113 (02) : 302 - 314
  • [67] HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma
    Liau, Siong-Seng
    Whang, Edward
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (05) : 1470 - 1477
  • [68] Constitutional rearrangement of the architectural factor HMGA2:: A novel human phenotype including overgrowth and lipomas
    Ligon, AH
    Moore, SDP
    Parisi, MA
    Mealiffe, ME
    Harris, DJ
    Ferguson, HL
    Quade, BJ
    Morton, CC
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2005, 76 (02) : 340 - 348
  • [69] NF-κB mediated transcriptional activation is enhanced by the architectural factor HMGI-C
    Mantovani, F
    Covaceuszach, S
    Rustighi, A
    Sgarra, R
    Heath, C
    Goodwin, GH
    Manfioletti, G
    [J]. NUCLEIC ACIDS RESEARCH, 1998, 26 (06) : 1433 - 1439
  • [70] HMGA1 protein over-expression is a frequent feature of epithelial ovarian carcinomas
    Masciullo, V
    Baldassarre, G
    Pentimalli, F
    Berlingieri, MT
    Boccia, A
    Chiappetta, G
    Palazzo, J
    Manfioletti, G
    Giancotti, V
    Viglietto, G
    Scambia, G
    Fusco, A
    [J]. CARCINOGENESIS, 2003, 24 (07) : 1191 - 1198